Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab.
Frilling
Birgit
B
Heart Center Ludwigshafen, Department of Cardiology, Ludwigshafen, Germany. frillinb@klilu.de
Zahn
Ralf
R
Fraiture
Boris
B
Mark
Bernd
B
Dönges
Klaus
K
Becker
Torsten
T
Siegler
Karl E
KE
Seidl
Karlheinz
K
Rustige
Jörg
J
Senges
Jochen
J
D000077284:Abciximab; D000368:Aged; D000789:Angina, Unstable / Q000150:complications / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications* / Q000628:therapy*; D023921:Coronary Stenosis / Q000150:complications / Q000628:therapy; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000150:complications*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab